310 related articles for article (PubMed ID: 29397528)
1. The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL).
Ma H; Davarifar A; Amengual JE
Curr Hematol Malig Rep; 2018 Feb; 13(1):13-24. PubMed ID: 29397528
[TBL] [Abstract][Full Text] [Related]
2. Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.
Marchi E; Raufi AG; O'Connor OA
Hematol Oncol Clin North Am; 2017 Apr; 31(2):359-375. PubMed ID: 28340883
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
Rogers AM; Brammer JE
Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
[TBL] [Abstract][Full Text] [Related]
4. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.
Nizamuddin I; Galvez C; Pro B
Semin Hematol; 2021 Apr; 58(2):85-94. PubMed ID: 33906726
[TBL] [Abstract][Full Text] [Related]
5. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.
Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
Crit Rev Oncol Hematol; 2016 Mar; 99():214-27. PubMed ID: 26811013
[TBL] [Abstract][Full Text] [Related]
6. New perspectives in the therapeutic approach of peripheral T-cell lymphoma.
Gisselbrecht C; Sibon D
Curr Opin Oncol; 2018 Sep; 30(5):285-291. PubMed ID: 30096094
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
[TBL] [Abstract][Full Text] [Related]
8. Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?
Lunning MA; Horwitz S
Curr Treat Options Oncol; 2013 Jun; 14(2):212-23. PubMed ID: 23568456
[TBL] [Abstract][Full Text] [Related]
9. Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials.
Ma H; Cheng B; Falchi L; Marchi E; Sawas A; Bhagat G; O'Connor OA
Hematol Oncol; 2020 Feb; 38(1):51-58. PubMed ID: 31872891
[TBL] [Abstract][Full Text] [Related]
10. Biomarker-driven management strategies for peripheral T cell lymphoma.
Mulvey E; Ruan J
J Hematol Oncol; 2020 May; 13(1):59. PubMed ID: 32448357
[TBL] [Abstract][Full Text] [Related]
11. Development of new agents for peripheral T-cell lymphoma.
Ito Y; Makita S; Tobinai K
Expert Opin Biol Ther; 2019 Mar; 19(3):197-209. PubMed ID: 30658046
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
Zhang P; Zhang M
Clin Epigenetics; 2020 Nov; 12(1):169. PubMed ID: 33160401
[TBL] [Abstract][Full Text] [Related]
13. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L; Mehta-Shah N
Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
[TBL] [Abstract][Full Text] [Related]
14. Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL).
Lu G; Jin S; Lin S; Gong Y; Zhang L; Yang J; Mou W; Du J
Clin Epigenetics; 2023 Aug; 15(1):124. PubMed ID: 37533111
[TBL] [Abstract][Full Text] [Related]
15. Contemporary strategies to improve outcomes for peripheral T-cell lymphoma patients following the failure of first-line therapy.
Kallam A; Armitage JO
Expert Rev Hematol; 2020 Jul; 13(7):745-753. PubMed ID: 32478625
[TBL] [Abstract][Full Text] [Related]
16. Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease.
Broccoli A; Argnani L; Zinzani PL
Cancer Treat Rev; 2017 Nov; 60():120-129. PubMed ID: 28946015
[TBL] [Abstract][Full Text] [Related]
17. Emerging strategies in peripheral T-cell lymphoma.
Mehta-Shah N
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):41-46. PubMed ID: 31808829
[TBL] [Abstract][Full Text] [Related]
18. [Current standard in diagnostic and therapy of peripheral T-cell lymphoma].
Hopfinger G; Staber P
Dtsch Med Wochenschr; 2019 Oct; 144(20):1400-1404. PubMed ID: 31594013
[TBL] [Abstract][Full Text] [Related]
19. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
Zain JM
Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
[TBL] [Abstract][Full Text] [Related]
20. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
Iyer SP; Foss FF
Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]